

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/541,708		ATTY. DOCKET NO.: A0848.70010US00	
				FILING DATE: July 8, 2005		CONFIRMATION NO.: 6032	
				APPLICANT: Karen Silence			
				GROUP ART UNIT: 1644		EXAMINER: Szperka, Michael Edward	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials ^a	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A4	5,916,805		Nagano et al.	06-29-1999
	A5	5,976,532		Coller et al.	11-02-1999
	A6	6,280,731		Nagano et al.	08-28-2001
	A7	6,793,920		Nagano et al.	09-21-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials ^a	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B2	WO	00/24781	A1	The Brigham and Women's Hospital, Inc.	05-04-2000	
	B3	WO	02/051351	A2	K. U. Leuven Research and Development	07-04-2002	
	B4	WO	2004/062551	A2	Ablynx N.V.	07-29-2004	
	B5	WO	2006/122825	A2	Ablynx N.V.	11-23-2006	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ^a	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C4	CONRATH, K.E. et al., "Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs," <i>The Journal of Biological Chemistry</i> 2001 Mar. 9; 276(10):7346-7350	
	C5	HULSTEIN, J.J. et al., "A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B," <i>Blood</i> 1 Nov. 2005; 106(9):3035-3042	
	C6	KAGEYAMA, S. et al., "Pharmacokinetics and Pharmacodynamics of AJW200, a Humanized Monoclonal Antibody to von Willebrand Factor, in Monkeys," <i>Arterioscler. Thromb. Vasc. Biol.</i> 2002 Jan.; 22:187-192	
	C7	MALLENDER, W.D. et al., "Construction, Expression, and Activity of a Bivalent Bispecific Single-chain Antibody," <i>The Journal of Biological Chemistry</i> 1994 Jan. 7; 269(1):199-206	
	C8	ROTE, W.E. et al., "Antithrombotic Effects of DMP 728, a Platelet GPIIb/IIIa Receptor Antagonist, in a Canine Model of Arterial Thrombosis," <i>Journal of Cardiovascular Pharmacology</i> 1994; 23:681-689	
	C9	SILENCE, K. et al., "ALX-0081 Nanobody (TM), an engineered bivalent anti-thrombotic drug candidate with improved efficacy and safety as compared to the marketed drugs," <i>Blood</i> 2006 Nov.; 108(11), Part 1, p. 269A	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

^a EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]